MAPT and tauopathy: While tau‐PET with [18F]PI‐2620 has emerged as a valuable biomarker in distinguishing the 4R tauopathies of PSP and CBS from healthy and disease controls,80, 82, 83, 84 the translation of in vitro 4R‐tau binding85 to in vivo tau‐PET signals remains unclear.